(Reuters) – Semnur Pharmaceuticals, a wholly owned subsidiary of Scilex Holding Company, will go public via a merger with special purpose acquisition company Denali Capital Acquisition Corp in a $2.5 billion deal, the companies said on Tuesday.
(Reporting by Jaiveer Singh Shekhawat in Bengaluru; Editing by Alan Barona)





Comments